MedPath

The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk

Not Applicable
Completed
Conditions
Diabetes
Prediabetes
Registration Number
NCT01972542
Lead Sponsor
Seoul National University Bundang Hospital
Brief Summary

The hypertriglyceridemia at fasting status has been known to be an important risk factor for cardiovascular disease (CVD). Recently, postprandial triglyceride (TG) levels draw an attention as a superior predictor of CVD because of non-fasting state for more than 12 hours and importance of triglyceride-rich lipoprotein.

We aim to investigate the relationship of postprandial triglyceride after fat tolerance test and intima-medial thickness and to suggest normal reference of postprandial triglyceride after fat tolerance test. In addition, we evaluate the correlation of postprandial triglyceride and incretin secretion after fat tolerance test Ultimately, we want to estimate clinical importance of postprandial triglyceride in assessment of cardiovascular risk.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • age : 19 ~ 70 yrs
  • Type 2 diabetes : HbA1c <10%
  • Prediabetic state : HbA1c 5.7~6.4%
Exclusion Criteria
  • Type 1 diabetes, secondary diabetes
  • dipeptidyl peptidase-4 -inhibitor, glucagon-like peptide-1 agonist, thiazolidinediones users
  • Thyroid disease with abnormal thyroid function test
  • Liver disease with abnormal liver function test
  • severe kidney disease
  • pregnant or lactating women
  • current smoker
  • severe obesity

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Changes of Triglyceride8 hours

Blood sample : drawn by a catheter before the meal and every 1 hour after meal over the 8-hour period

Secondary Outcome Measures
NameTimeMethod
Changes of incretin8 hours

Trial Locations

Locations (1)

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Korea, Republic of

Seoul National University Bundang Hospital
🇰🇷Seongnam, Korea, Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.